Please login to the form below
respiratory
This page shows the latest respiratory news and features for those working in and with pharma, biotech and healthcare.
Relief Therapeutics seeks US emergency approval for COVID-19 drug
According to Relief Therapeutics, patients treated with RLF-100 demonstrated a three-fold advantage in survival, as well as recovery from respiratory failure and other clinical improvement parameters. ... VIP has been shown in over 100 peer-reviewed
Latest news
-
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. ... linked to an increased susceptibility to develop severe
-
Standard steroid improves recovery of critically-ill COVID-19 patients
The study evaluated hydrocortisone in 403 patients with suspected or confirmed COVID-19, who required respiratory or cardiovascular organ support.
-
Roche plans to launch rapid COVID-19 antigen test later this month
The Winterplex test includes two gene targets specific to COVID-19, as well as gene targets for influenza A and B and respiratory syncytial virus (RSV).
-
Novacyt launches diagnostic test to differentiate between COVID-19 and flu
The new polymerase chain reaction (PCR) respiratory test can be used on any open PCR platform, including Novacyt’s portable q32 instrument. ... We believe Winterplex is one of the world’s first approved respiratory test panels that can differentiate
-
Takeda to sell Japan consumer health unit for $2.3bn
The Stada deal includes OTC vitamins and food supplements, and select products in the cardiovascular, diabetes, general medicine and respiratory therapeutic areas.
More from news
Approximately 28 fully matching, plus 583 partially matching documents found.
Latest Intelligence
-
Could formulary intelligence be your brand differentiator?
Five years ago, we tracked the Y1 formulary adoption of five high-profile UK product launches in respiratory and diabetes.
-
Has AI been the key to tackling the COVID-19 pandemic?
and monitor the virus more efficiently. By using its algorithm to locate the virus on images of patients’ lungs, as distinct from other respiratory infections, it minimises the burden on medical
-
A snapshot of… Enterprise Therapeutics
Enterprise’s management team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. ... In many respiratory diseases, however, the mucus becomes thick and sticky, with the solids rising to > 10%.
-
COVID-19: the race to find a vaccine
Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.
-
GSK forges ahead with its dynamic COPD and asthma portfolio
joined the company in 2013 after a distinguished clinical career as Consultant Respiratory Physician at London Chest Hospital, Barts Health NHS Trust, in London, UK. ... COPD was a Cinderella disease when I started in respiratory medicine but it is
More from intelligence
Approximately 1 fully matching, plus 78 partially matching documents found.
Latest appointments
-
McCann Health North America appoints Jim Joseph as president
Joseph also has expertise in a number of therapeutics areas, including cardiovascular, upper respiratory, HIV, dermatology and more.
-
AstraZeneca taps internal candidate to become UK president
Most recently, he served as senior vice president of the company’s global respiratory and immunology franchise.
-
New hires at Crescendo, Healx and Galecto
Prior to eTheRNA, Lindmark served as global VP of clinical development for the respiratory and inflammation franchises at AstraZeneca. ... In that role, he led the development of Symbicort, a leading respiratory brand.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;
-
Alexion appoints new senior VP for EMEAC region
Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology.
More from appointments
Approximately 0 fully matching, plus 49 partially matching documents found.
Latest from PMHub
-
After a busy first quarter, emotive welcomes five new team members
Not only does Dorothy bring with her solid experience in diabetes, CVRM, respiratory and nutrition, she expands emotive’s wide language repertoire to include Mandarin Chinese. .
-
Covid-19 drives change in long-term conditions management
Remote monitoring is key to enabling more people to successfully manage their conditions at home and one area in which it can be successfully deployed is in respiratory diseases. ... In common with many other long-term condition patients, people with
-
Understanding COVID-19 and varying responses across the globe
However, COVID-19 is thought to have come possibly from bats. The symptoms can range from mild to severe, all affecting the respiratory system, from fever and fatigue to complete respiratory ... There are three main ways that respiratory viruses are
-
Covid-19: how is it impacting on the NHS Long-term Plan?
To help manage care during the crisis, NHS England has issued a series of guides outlining how patients with conditions ranging from cardiovascular to diabetes and respiratory conditions should be treated
-
"New models" for agency pitching. My "Top takeaways" from the PM Society event
GSK’s work to do this in their recent Global Respiratory pitch was industry-leading and significantly based on “chemistry”.
More from PMHub
Approximately 2 fully matching, plus 29 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- Moderna inks R&D agreements with Vertex and Chiesi
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
Spirit
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
